DESCRIPTION (provided by applicant): In response to increased concern about emerging and re-emerging infectious diseases, particularly Class A-C agents that could be used as weapons of bioterrorism, the microbiology community at the University of Pennsylvania proposes to establish a Training Program in Emerging Infectious Diseases. The Training Program would initially support two Ph.D. and two M.D./Ph.D. or V.M.D./Ph.D. predoctoral fellows as well as three postdoctoral fellows, enabling them to work in any one of 14 laboratories directed by Principal Investigators who study important viral or parasitic pathogens that are classified as either emerging or re-emerging threats to human health. The trainers associated with this T32 proposal have been selected because their research programs in these areas are well-established and are being supported by NIH grants and/or have published papers on this topic. The trainers study a number of important viral and parasitic pathogens. Six of the trainers on this grant study smallpox proteins or are developing anti-vaccinia agents, and currently hold one R01, two R21s and one U01 grants to support work in this area (Isaacs, Rosengard, Cohen, Eisenberg, Friedman, Ricciardi). Four trainers on this grant study Ebola virus, holding one R01 and two R21 grants and having published several papers in the last two years (Bates, DoTs, Shen, Harty). Collaborations with colleagues at USAMRIID make it possible to perform experiments with live Ebola virus. Other important emerging viral diseases that are subjects of significant research efforts by the trainers include West Nile virus and Dengue (DoTs, Bates). Emerging and re-emerging parasitic diseases are the focus of research efforts by the trainers and include Malaria, a major focus of the Roos laboratory which plays a major role in managing the Plasmodium genome project. Outbreaks of leishmaniasis (Scott) in Afghan refugee camps in Pakistan and other regions, have demonstrated increased incidence of old infections from a confluence of wars, population shifts, and development into little populated regions. Due to climactic changes and large-scale water resources development projects, there have been notable new outbreaks of schistosomiasis in previously unaffected areas (Pearce, Shen). Increased infections due to toxoplasma gondii have also been reported (Roos, Hunter). With time, we anticipate that other Penn investigators will join this training program as they shift their research focus to include emerging infectious diseases. The research opportunities provided by the trainers coupled with strong institutional commitment and an extensive and well-organized training program will provide excellent training in emerging infectious diseases to students and postdoctoral fellows.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
042250712
UEI
GM1XX56LEP58
Project Start Date
01-August-2003
Project End Date
31-July-2008
Budget Start Date
01-August-2005
Budget End Date
31-July-2006
Project Funding Information for 2005
Total Funding
$241,019
Direct Costs
$228,055
Indirect Costs
$12,964
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$241,019
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5T32AI055400-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5T32AI055400-03
Patents
No Patents information available for 5T32AI055400-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5T32AI055400-03
Clinical Studies
No Clinical Studies information available for 5T32AI055400-03
News and More
Related News Releases
No news release information available for 5T32AI055400-03
History
No Historical information available for 5T32AI055400-03
Similar Projects
No Similar Projects information available for 5T32AI055400-03